pharmaceutical marketing plan case study

Ready for launch: Reshaping pharma’s strategy in the next normal

As COVID-19 cases continue to spread across the globe, the repercussions in healthcare extend across the value chain from patients and families to clinicians and pharmaceutical companies.

The industry faces a dual challenge. As well as helping to tackle COVID-19 spread by developing and distributing new vaccines and tests, it must continue to deliver innovative therapies and diagnos­tics to clinicians, patients, and healthcare systems—even as R&D, manufacturing, and supply chains are struggling to maintain business as usual.

An earlier McKinsey article considered how pharma companies can reorient their commercial model to respond to the new environment. Below, we focus on launch activities and identify five success factors to consider for commercial launches in the next normal.

Familiar challenges and new complications

Even before the COVID-19 outbreak, launching a new drug was far from straightforward. Forty percent of worldwide drug launches between 2009 and 2017 failed to meet their two-year sales forecasts. 1 McKinsey analysis of pharmaceutical-industry data from Evaluate, August 2020. A successful launch must overcome a series of barriers, including intensifying competition, increasing pricing pressure, growing access challenges, and rising expectations among caregivers and patients. The pandemic and its economic consequences have added further complications to what was already a risky launch environment.

We analyzed 86 launches scheduled for 2018 onward with expected sales in excess of $300 million. We found that between February and August 2020, all of these launches were disrupted through delays, lost revenues, or both. Companies chose to delay launches in 45 percent of cases, regulatory delays affected another 40 percent, and other external factors such as supply-chain problems accounted for the remaining 15 percent of delays. 2 This article draws on insights from a global survey conducted by McKinsey in June 2020 among 101 managers with recently launched drugs that had not reached their peak sales or drugs scheduled for launch between January and June 2020 that had been delayed. In the United States, for instance, the median interval between approval and first scripts had increased more than threefold by May 2020, from 17 to 58 days, although it shrunk back to 21 days by September. 3 McKinsey analyzed products launched from March 2020 or awaiting launch, using data from PHAST (Pharmaceutical Audit Suite) and Evaluate. For products not yet launched, the interval between the FDA-approval date and September 2020 was used as a proxy for the interval between approval and launch.

The pandemic also had a marked impact on the financial performance of the launches we analyzed. In 50 out of the 86 disrupted launches, companies lowered their expectations by more than 25 percent. Overall, we estimate that the changes in analyst consensus expectations between March and August 2020 represent a 9 percent decline in the net present value of the 86 drugs—the equivalent of a total loss of some $10 billion globally. 4 McKinsey used August 2020 data from Evaluate and estimates from March 2020 or earlier to calculate how the net present value of the 86 drugs changed in the months following the outbreak of COVID-19.

Why the traditional launch model is losing effectiveness

It is too soon to evaluate the full impact of the COVID-19 pandemic on drug launches. However, it is clear that major shifts in the way that healthcare professionals (HCPs) interact with pharma companies will present a challenge for the traditional launch model, with its reliance on face-to-face meetings with physicians and its “one size fits all” approach to engagement.

One immediate consequence of the pandemic has been a drastic reduction in pharma companies’ visits to HCPs. A survey conducted by McKinsey in Europe shows that the average number of in-person contacts between HCPs and pharma sales reps was 70 percent lower in September 2020 than before the pandemic. 5 McKinsey COVID-19 Survey: EU Physician Experiences, Expectations, and Perspectives on Pharma Engagement; survey in the field in May and September 2020. In parallel, HCPs’ adoption of digital channels and telemedicine has accelerated for interactions with patients and pharma reps alike. In the same survey, the HCPs who are highly open to remote engagement with sales reps report conducting almost half of their patient consultations remotely as well.

However, this broad overview masks considerable differences in HCPs’ preferences and expectations. A McKinsey survey conducted in May and September 2020 to assess sentiment among more than 900 physicians in five European countries yielded a patchwork of responses (Exhibit 1).

Only 18 percent of the physicians surveyed in May were willing to accept reps’ visits, but by September, that percentage had risen to 31 percent, suggesting that preferences shift over time as infection rates change and HCPs adjust to new circumstances. 6 McKinsey COVID-19 Survey: EU Physician Experiences, Expectations, and Perspectives on Pharma Engagement; survey in the field in May and September 2020. Preferences also vary by country. In the September survey, more than 50 percent of HCPs in France, Germany, and Italy expressed a willingness to accept regular face-to-face visits from reps, but only 11 percent of their UK peers felt the same way.

These findings suggest that the traditional pharma commercial model will likely struggle to adapt to a different world. When reps venture back into the field, they will need to address the plurality and access challenges of the new interaction landscape. To do that, they will need to consider a new approach to launches: one that is digital, local, and personalized.

What next? Five success factors to consider for a launch strategy

For a pharma company looking to reinvent its commercial model, the launch of new products is a golden opportunity to try out new techniques and gauge their impact before rolling them out more widely. Given the uncertainties triggered by the pandemic and the radical changes in physicians’ preferences and behaviors, replicating successful launch strategies from the past is no longer a safe option. Our work with pharma companies indicates that leaders designing a new strategy should consider paying close attention to five success factors: rapidly personalized content, analytics-enabled engagement, innovative patient channels and services, nimble frontline operations, and closed-loop execution (Exhibit 2). We outline each of these five factors in greater detail below.

Rapidly personalized content

With HCPs’ preferences so variable and changeable, pharma companies need clear, up-to-date per­spectives on each physician’s interests and wishes so they can gear messages to individual needs and concerns. Basing communications on an undifferentiated aggregate view of physicians or segments will no longer suffice. For each new product launch, best-practice companies compile a set of marketing and medical modules to cover the full spectrum of HCP needs and then ask reps to use their insight into individual physicians to select the modules that best meet their needs.

While this approach has been true for many years, the difference is that today those new modules need to be created quickly to be relevant. A better way to stay relevant is to engage HCPs on the current hot topics in their field—for example, what best practices are emerging in telemedicine? How are HCPs managing COVID-19 infection risk for patients? What do key opinion leaders think about the potential for drug-to-drug interactions with COVID-19 vaccines?

Familiar product-oriented and company-centered approaches to content may also need rethinking. To reduce development cycles, content creation and review processes need to be streamlined and simplified. With agile approaches, companies can book a meeting with an HCP, gather feedback, and capture it immediately in the next iteration of content development. In that way, content can be approved and refined within approval cycles of no more than two to four weeks.

For a pharma company looking to reinvent its commercial model, the launch of new products is a golden opportunity to try out new techniques and gauge their impact before rolling them out more widely.

Analytics-enabled engagement

If a universal approach is no longer an option for content, the same is true of engagement. The days of casual appointments and conversations in hallways are over. Whether an interaction is face to face or remote, it needs to be scheduled and an agenda shared in advance. A rep needs to have something new and compelling to discuss or risks that the meeting might never happen.

To understand individual physicians’ preferences for interaction frequency and channels, innovative companies are creating data lakes, building predic­tive models, and drawing on unfamiliar data sources—not only customer-relationship-management (CRM) systems, sales records, and quantitative surveys, say, but also claims data for providers at a physician’s office. Innovative approaches can yield surprising results. In the United States, for instance, some pharma com­panies found they can predict physicians’ willingness to engage with reps more accurately from foot traffic and credit-card spend in a given zip code than from local state restrictions or COVID-19 infection rates.

Since relevant historical data on physician prefer­ences on interactions with sales reps is seldom available at launch, the process of generating insights typically begins with field reps reporting on the impressions they gained of HCPs’ preferences during prelaunch interactions with them. As the product launch progresses, important factors such as physi­cian feedback, field insights, and prescription volume are used to flesh out and update this prelimi­nary picture. Through a continual process of refinement, the predictive model on launch success becomes more powerful and its output better aligned with the realities of the market. As a physician’s preferences evolve—both in response to the new product as well as in engagement channels—the model adjusts its recommendations, enabling reps to fine-tune content and channel choices for an audience of one to provide an optimal personalized experience at launch.

To implement an analytics-based approach to engagement, pharma leaders also need to ensure that two critical enablers are in place: a tech and data backbone to enable seamless integration across channels and data sources, and a platform for run­ning advanced-analytics models to enable leaders to distinguish signals from noise, improve deci­sion making in real time, and optimize messages, channels, and timing in individual HCP interactions.

Innovative patient channels and services

In a McKinsey survey of 300 physicians in September 2020, 74 percent of respondents reported noticing their patients delaying necessary care, with conse­quences including an increase in complications from injury or disease, a loss of income from missing work, and a rise in the costs of care. For new product launches, this finding is significant, since patients who have yet to be treated for a new medical condition are often the ones most interested in a new product for treat­ment. However, as patients delay care due to the COVID-19 pandemic, the pool of new patients that may have benefited from being treated with a new product is declining as well. The new hurdles created by the COVID-19 pandemic call for innovative services from pharma companies, as well as from healthcare systems and professionals, to stay connected with patients.

As the survey indicates, the perceived risk of engag­ing with health systems has made many patients wary of face-to-face interactions in all but the most serious cases. Those suffering from nonurgent conditions, such as migraines, insomnia, and depres­sion, are less likely to request appointments with primary-care physicians. Responsive companies have been stepping in to facilitate inter­actions with HCPs by offering telemedicine diagnostic platforms in app form or through the integration of web, text, and voice.

Maintaining or adjusting treatment can also be dif­ficult in today’s circumstances, especially for infusions, injections, and other therapies that require attendance at a hospital or clinic. Innovative companies are developing alternative infusion sites, enabling “at home” infusion, and offering guidance on how to minimize risk when visiting health facilities.

Nimble frontline operations

As pharma companies gear up for remote launch activities, they can help their sales reps build new capabilities that can enhance their impact on launch success. As virtual calls replace in-person visits, reps can foster a sense of proximity with HCPs by learning to make the most of cameras, screen sharing, and other interaction tools. Soft skills such as deep listening will help sales reps gather insights on physicians’ unmet needs and sources of dissatisfaction. Feeding these insights back into CRM systems will enhance their predictive power and enable the organization to rapidly correct course where needed.

As the use of video, interactive content, and multi­person interactions increases, companies will also need to rethink marketing materials so that they are effective in remote settings. Meanwhile, marketing staff will need to further develop their ability to optimize marketing campaigns based on HCP engagement, as well as using CRM data and dashboards to assess the effectiveness of past and future actions. Capability-building programs will equip staff with the soft and hard skills— from empathy to proficiency with advanced digital tools—required for success in a rapidly changing launch environment.

Capabilities aside, launch programs give companies an opportunity to reassess the setup of their field force. With less time spent traveling and waiting to see HCPs, reps have more capacity to pursue value-added opportunities. One example might be expanding physician engagement beyond the treatment network—through referral networks, for instance—especially now that location is no longer a constraint. Building a fuller view of customer-facing roles and interactions should allow launch leaders to allocate frontline capacity in a more effective and granular manner.

Closed-loop execution

Today’s environment makes agile ways of working a necessity. With launches no longer following a common regional or national strategy but tailored to suit local contexts, each initiative must be tracked and redirected in real time as early feedback and results on sales tactics are gathered. This kind of closed-loop execution requires changes in governance and in how decisions are made.

For instance, regional leads should be empowered to fine-tune targeting philosophy and product positioning in response to the feedback they gather locally. Meanwhile, central launch teams can share best practices or make suggestions by aggregating the success rate of different approaches across various target segments and regions. Campaigns that prove effective can be scaled up across broader geographies, while ineffective campaigns can be replaced with new campaigns that are tested and, in turn, refined or replaced as needed based on their results. Consequently, launch plans are updated in rapid iterations at national and regional levels to ensure that insights and opportunities are fully captured. To manage this process and experiment with new methods and ways of working, some companies set up launch situation rooms  that pull together data on sales, volume uptake, and other standard metrics with field insights garnered through rep apps to analyze launch performance in real time. Adopting an agile operating model with processes that support cross-functional collaboration enables launch teams to rapidly create campaigns to address shifting customer needs.

The turbulence of the past few months has made pharma companies keenly aware of the need to rethink their medical education, engagement channels, and platforms—but it has also left some of them paralyzed by uncertainty. Should they invest now in transforming their commercial model or wait to see how things play out? As com­mercial leaders consider their go-to-market plans for new drugs, they have a unique opportunity to experiment with new approaches without disrupting their entire business model. Innovations developed for new drugs that prove valuable for commercial success will reshape the commercial strategy of the whole company.

Arafat Mlika is an associate partner in McKinsey’s Geneva office, Jennifer Mong is a consultant in the Silicon Valley office, Nils Peters  is a partner in the Zurich office, and Pablo Salazar is a partner in the Stamford office.

Explore a career with us

Related articles.

COVID-19 and commercial pharma: Navigating an uneven recovery

Winning against COVID-19: The implications for biopharma

How to Nail Your Pharma Marketing Strategy

By Adriana Stein

Table of contents.

The only way to get your products in the hands of your target customers is to develop effective marketing strategies that make you stand out. 

Here is where having a targeted pharma marketing strategy comes in.

Doctors heavily influence the type of prescription drugs patients use, which means that your marketing strategy should consider how doctors think when deciding which drug is the best for their patients’ conditions. 

For non-prescription drugs, patients usually prefer the ones with a marketing message that resonates with their symptoms and concerns. They also trust drugs that fellow patients recommend.

In this article, we teach you how to adapt your message for patients, doctors, and B2B partners and convince them that your pharma interventions are safe and effective. 

What is pharma marketing?

Pharma marketing refers to strategies that help pharmaceutical companies achieve their business goals by drawing physicians and patients to their brand. 

Even though drug affordability and disease prevalences continue to drive the growth rate of the pharmaceutical industry, government regulations slow it down. According to the Pharmaceutical Drugs Global Market Report , the pharmaceutical industry is growing at the rate of 5% which is behind only two other healthcare segments: medical services and equipment.  

Despite the tight regulations and policies of the governments in different countries, the demand for pharmaceutical drugs is only likely to rise. This is because the pharmaceutical industry is one of the most profitable and in-demand industries in the world. 

So how exactly do you beat your competition to win the trust of patients and physicians?  

It is through understanding the consumer needs and finding the solutions to meet these needs.

Successful marketing in the healthcare industry depends significantly on trust and brand transparency. The best way to develop trust with your target clients is to show them how your product helps them solve their problems. By demonstrating its features transparently, including its efficacy and side effects, physicians begin to trust you and prescribe your product to their patients.     

4 reasons why you need to invest in a well-designed pharma marketing plan

There are three types of target customers in the pharmaceutical industry: doctors, patients, and B2B partners. Most companies aim at developing strong relationships with physicians because they have a considerable influence over the type of drug patients will purchase. Content marketing that is clear and well-researched convince physicians to go with your brand. 

Here are the benefits an effective pharmaceutical marketing strategy delivers to your business:

#1 Increases sales 

Pharma marketing improves your sales because tailored messages meet the needs of your target customers. Doctors will only prescribe your product to their patients once they review the studies that prove its efficacy in treating a specific disease. By coming out clearly on the features of your drug, including its proven benefits and side effects, healthcare experts will trust you more. 

#2 Improves brand awareness

Thoughtful and targeted marketing messages get your brand in front of your ideal customers. With improved brand awareness and reliable products, you steadily grow your brand authority. 

#3 Strengthens relationships with customers

Strong relationships in the pharma industry are formed when your product improves patients’ well-being. A patient who has experienced health improvements thanks to your products is likely to share its benefits to the world.

As part of your well-defined pharma marketing plan, you should be active on such platforms and engage with your audience. This enhances your brand awareness and shows your customers that you are available and ready to help them. 

#4 Triggers product development  

Understanding how customers feel about your brand, services, and products is vital to promote the right marketing messages. In the pharmaceutical industry, feedback helps you improve various features of your drugs through comprehensive research and how you communicate with your audience. 

A 5-step pharma marketing plan

So how do pharmaceutical companies market their products? Successful marketing strategies in the pharma industry focus on physicians and patients. The marketing messages presented to physicians are supported with proven research about the efficacies and side effects of the drugs. 

Here is a 5 step pharma marketing strategy that will help you get ahead of your competition.

#1 Creating buyer personas

Every successful pharma marketing strategy starts with defining your target patients and physicians. This improves your pharma marketing ROI (return on investment) because the messages are tailored to meet a specific patient’s needs. 

A buyer persona is an ideal customer with a specific set of challenges that your product solves. Having a deeper understanding of what your target doctors consider about a drug before prescribing it to their patients helps you craft compelling messages in the healthcare industry.

#2 Content marketing

Content marketing in the pharmaceutical industry enables you to showcase the features of your product to doctors and patients. While there are different forms of content marketing that you can use to present your product to doctors and patients, many countries have strict regulations on which types of content you can promote. This is because some pharma companies may portray a drug as having features that may not be true. So when using content marketing, make sure you do so legally and transparently.

#3 Case studies

Case studies are a great way to show how your products have helped people and ultimately win doctors’ and patients’ trust. A case study presents the results your customer received after using your product over a specific period. 

In pharmaceuticals, it points to the challenges of the target patient before consuming your drug and the solutions your drug offers. It is like a detailed testimonial. 

The strength lies in the symptoms that your drug was able to treat. If your target patients’ condition aligns with these symptoms, they will be encouraged to try your medication in the hope that they get the same relief.  

#4 Email marketing and list building

Email marketing is one of the oldest marketing tricks in digital marketing, and it is still effective if used in the right way. Emails remain the most personalized way to communicate with your target audiences. It allows you to empathize with their conditions and show how your medication may relieve their symptoms. Using marketing automation , you can reach thousands of patients and doctors who are part of your email list personally and develop deep relationships that transform into sales. 

When creating an email list, you should implement lead generation strategies such as white papers, checklists, webinars, and ebooks. Patients and doctors who are interested in your resources download them in exchange for their emails. Once you capture their emails, you begin providing relevant information about how your drug can help them treat their conditions, hoping that they will purchase it.  

SEO helps your website’s content rank high on search results and increase organic traffic.

As a pharmaceutical company, SEO best practices help you increase the number of relevant physicians and patients who visit your site through targeted searches on the internet. Valuable and educational content helps them learn about the benefits and advantages of your drug. 

SEO best practices include building your content around specific keywords related to the diseases your drugs can treat, building backlinks, guest posting, and much more.   

How to adapt your pharmaceutical marketing to specific  audiences

There are three primary audiences in the pharmaceutical industry: doctors, patients, and other healthcare companies. By learning their needs and motives, your marketing approach is tailored to increase the chances of selling them your drugs. 

Here’s how to use your pharma marketing plan to target each of your audiences.

Marketing to doctors

Marketing to doctors involves giving them detailed information about your product to help them decide whether they can prescribe it to their customers.

To gain the trust of doctors, you should provide scientific evidence about your products, including their benefits and side effects. You can create content such as case studies and in-depth research showing the results of the phases of clinical trials of a drug. 

Marketing to patients

Most patients tend to trust their doctors’ prescriptions whenever they get sick. However, outbound marketing methods such as radio ads and TV ads can influence patients to ask their doctors about a specific treatment. If you promote the right message through the proper communication channels, patients will be encouraged to ask for or use your medication.   

B2B pharmaceutical marketing

There are pharmaceutical products not used directly by patients. These include items such as laboratory equipment, medical devices, and medical tests. In these instances, you need to target B2B partners to sell your pharmaceutical products to. Writing case studies is one of the best ways to inform other medical businesses and B2B partners about your products. 

About the Author

Adriana Stein is an Online Marketing Consultant based in Hamburg, Germany. Originally from the US, she is a native English speaker and specializes in helping companies with their SEO & content marketing strategies, along with graphic design, brand copy and website development.​

Real people, real results, real international market growth

“Working with the AS Marketing team has been a pleasure. The team was able to not only craft a content and email marketing strategy to help us reach our goals, but also to lead us throughout the whole implementation process with dedication and expertise. I would highly recommend them to any company looking to up its game in content marketing.”

Tobias Arns

Chief Marketing Officer, Kindly

“AS Marketing has been very helful in developing and executing our SEO content plan. Before working with her, we didn’t know how to approach our content marketing in an efficient and cost-effective way. But from day 1, Adriana gave us a concrete plan that was really centered on the needs of our customers. Thanks to her, our organic traffic continues to increase, and with that, our user base and revenue. We’ve never worked with an SEO consultant like her before with suck a holistic and customer-centric approach to marketing.”

Anja Zschörnig

“With the launch of the new company, we were looking for an agency to place us effectively. We started working with AS Marketing, and so far, it has been really good. Not having to micromanage the project was one of the key advantages of working with them. While it’s only been 6 months, I am sure we will have our desired results in a year. AS Marketing delivers regular content and audits, so we know we are on the right truck.

Kanika Choudhary

Brand Marketing Manager, Restructum

Looking to expand into new markets?

Related posts.

Sign up to get free access to our latest masterclass and more >

Powering Growth: Game-Changing Marketing Trends in the Pharma Sector

Evolution of Marketing in the Pharma Sector

The pharmaceutical industry has witnessed a significant evolution in marketing approaches over the years. Traditional marketing methods that were once effective are now being challenged by the need for innovation and adaptation in an ever-changing landscape.

Traditional Marketing Approaches in Pharma

Traditionally, marketing in the pharma sector relied heavily on methods such as print advertisements, television commercials, and direct sales representatives. These approaches were effective in reaching healthcare professionals and driving brand awareness. However, they often lacked the ability to directly engage with patients and deliver personalized messaging.

The limitations of traditional marketing approaches became evident as consumer behavior shifted towards digital channels. Patients started seeking information online and engaging with healthcare-related content on social media platforms. This shift in behavior called for a new approach to marketing in the pharma sector.

The Need for Innovation and Adaptation

To stay relevant and effectively reach their target audience, pharmaceutical companies recognized the need for innovation and adaptation in their marketing strategies. This led to the emergence of new techniques such as omnichannel marketing and programmatic advertising.

By embracing omnichannel marketing , pharmaceutical companies can create a seamless and integrated customer experience across multiple channels. This approach allows for personalized messaging and engagement with patients throughout their healthcare journey. Pharmacies, clinics, and online platforms can all be part of the omnichannel experience, ensuring consistent communication and a holistic approach to marketing.

In addition to omnichannel marketing, programmatic advertising has also gained traction in the pharma sector. Programmatic advertising leverages data and automation to optimize ad placements in real-time, reaching the right audience at the right time. This approach allows for precision targeting and efficient use of advertising budgets.

By embracing these innovative marketing strategies, pharmaceutical companies can adapt to the changing landscape of consumer behavior and effectively reach their target audience. The integration of omnichannel marketing and programmatic advertising enables personalized messaging, precise targeting, and improved patient engagement.

As the pharmaceutical industry continues to evolve, staying ahead of the curve in terms of marketing strategies is essential. By embracing the power of digital marketing, automation, and data-driven approaches, pharmaceutical companies can effectively navigate the challenges and opportunities of the modern marketing landscape. For more information on pharma digital marketing strategies, visit our article on pharma digital marketing strategies .

Understanding Omnichannel Marketing in Pharma

In the rapidly evolving world of pharmaceutical marketing, it is imperative for companies to stay ahead of the curve and adapt to the changing landscape. One of the key trends driving success in the pharmaceutical industry is omnichannel marketing. This section will provide a clear understanding of what omnichannel marketing entails and the core principles behind it, as well as the benefits and advantages it offers.

Definition and Core Principles

Omnichannel marketing in the pharmaceutical industry refers to the strategic approach of providing a seamless and integrated customer experience across multiple channels and touchpoints. It involves creating a cohesive brand message and delivering it consistently across various online and offline platforms. The core principles of omnichannel marketing include:

Consistency : Ensuring that the brand message, content, and visual identity remain consistent across all channels, including websites, social media, email marketing, and offline marketing materials.

Personalization : Tailoring marketing efforts to the specific needs and preferences of individual customers. This can be achieved through data analysis and segmentation, allowing for targeted messaging and personalized experiences.

Integration : Creating a unified customer journey by integrating various channels seamlessly. This includes enabling customers to transition effortlessly between online and offline touchpoints.

Data-driven Insights : Leveraging data and analytics to gain insights into customer behavior, preferences, and engagement. This data can then be used to optimize marketing strategies and refine the customer experience.

Benefits and Advantages of Omnichannel Marketing

Omnichannel marketing offers a range of benefits and advantages for pharmaceutical companies. Here are a few key advantages:

Enhanced Customer Experience : By providing a seamless and consistent experience across channels, pharmaceutical companies can improve customer satisfaction and loyalty. Customers can interact with the brand through their preferred channels, leading to a more positive and engaging experience.

Increased Engagement and Reach : Omnichannel marketing allows pharmaceutical companies to reach a wider audience by leveraging multiple channels. This increases brand visibility and enables companies to connect with customers at various stages of their healthcare journey.

Improved Targeting and Personalization : By leveraging data and analytics, pharmaceutical companies can gain valuable insights into customer preferences and behaviors. This enables targeted messaging and personalized experiences, leading to higher engagement and conversion rates.

Optimized Marketing Strategies : With access to data-driven insights, pharmaceutical companies can continuously refine their marketing strategies. They can identify the most effective channels, messaging, and content, resulting in more efficient resource allocation and improved ROI.

By understanding and implementing the principles of omnichannel marketing, pharmaceutical companies can effectively navigate the evolving marketing landscape, engage with customers on a deeper level, and drive business growth. To learn more about the impact of digital marketing strategies in the pharmaceutical industry, check out our article on pharma digital marketing strategies .

Implementing Omnichannel Marketing Strategies

To effectively implement omnichannel marketing strategies in the pharmaceutical industry, two key components are crucial: data-driven targeting and personalization, and ensuring a seamless customer experience across channels.

Data-driven Targeting and Personalization

Data-driven targeting and personalization play a vital role in omnichannel marketing strategies for the pharmaceutical industry. By harnessing the power of data, pharmaceutical companies can gain valuable insights into their target audience, enabling them to create highly targeted and personalized marketing campaigns.

Through the collection and analysis of data, pharmaceutical brand managers can identify key demographic information, preferences, and behaviors of their target audience. This information allows them to tailor their marketing messages and deliver them through the most effective channels. By understanding their audience on a deeper level, pharmaceutical companies can ensure their marketing efforts resonate with their target customers.

Utilizing marketing automation tools can be instrumental in implementing data-driven targeting and personalization strategies. These tools enable the segmentation of customer data, allowing pharmaceutical companies to deliver personalized content and messages to specific customer groups. For more information on pharma marketing automation, refer to our article on pharma marketing automation .

Seamless Customer Experience Across Channels

Creating a seamless customer experience across channels is a key objective of omnichannel marketing in the pharmaceutical industry. Customers today interact with brands through various touchpoints, such as websites, social media, email, and mobile applications. To provide a consistent and cohesive experience, it is essential to ensure that the messaging, branding, and user experience are harmonized across all channels.

To achieve a seamless customer experience, pharmaceutical companies should focus on integrating their marketing efforts across different channels. This includes aligning the messaging and visuals to create a unified brand experience. By maintaining consistent branding and messaging, pharmaceutical companies can build trust and recognition with their audience, regardless of the channel they are engaging with.

Furthermore, optimizing the user experience across channels is paramount. Pharmaceutical companies should ensure that their websites and mobile applications are user-friendly, responsive, and provide a smooth navigation experience. This allows customers to easily access the information they need and engage with the brand effortlessly.

By implementing data-driven targeting and personalization strategies and ensuring a seamless customer experience across channels, pharmaceutical companies can effectively leverage omnichannel marketing to reach and engage their target audience. This integration of omnichannel marketing and programmatic advertising strategies is crucial for staying ahead of the curve in the rapidly evolving pharmaceutical industry.

Programmatic Advertising in Pharma

In the ever-evolving landscape of marketing, programmatic advertising has emerged as a game-changing approach, even within the pharmaceutical industry. This section will explore the concept of programmatic advertising and its specific applications in the pharma sector.

What is Programmatic Advertising?

Programmatic advertising refers to the automated buying and selling of digital advertising space in real-time. It utilizes advanced technologies, such as artificial intelligence and data analytics, to streamline the process of ad placement and optimization. By leveraging algorithms and data-driven insights, programmatic advertising allows for precise targeting and efficient delivery of ad content.

In programmatic advertising, the buying and selling of ad inventory occur through real-time auctions. Advertisers can define their target audience based on various parameters, such as demographics, interests, and online behavior. The system then matches the available ad inventory with the most relevant audience segments, ensuring that the right message reaches the right people at the right time.

Programmatic Advertising in the Pharma Sector

The pharmaceutical industry has recognized the potential of programmatic advertising to enhance their marketing efforts. Programmatic advertising offers several key advantages for pharma brands, including increased efficiency, precision targeting, and enhanced campaign performance.

One of the primary benefits of programmatic advertising in the pharma sector is the ability to reach highly specific and niche audiences. Pharmaceutical products often cater to particular medical conditions or patient demographics. Through programmatic advertising, pharma brands can leverage data-driven targeting and audience segmentation to deliver tailored messages to the right individuals. This precision targeting not only increases the relevance of the ads but also optimizes the return on investment (ROI) of marketing campaigns.

Moreover, programmatic advertising enables real-time optimization and efficiency. Advertisers can monitor the performance of their campaigns in real-time and make adjustments as necessary. This allows for continuous optimization of ad placements, creative elements, and messaging to maximize engagement and conversion rates. By utilizing programmatic advertising, pharma brands can ensure that their marketing efforts are cost-effective and yield measurable results.

To stay ahead in the competitive pharma industry, it is crucial for brands to embrace the opportunities presented by programmatic advertising. By integrating programmatic strategies into their overall marketing approach, along with omnichannel marketing , pharma brands can effectively target their desired audience segments and achieve their marketing objectives.

In the next section, we will explore the ways in which programmatic advertising can be leveraged for success in the pharmaceutical industry, focusing on precision targeting and audience segmentation, as well as real-time optimization and efficiency.

Leveraging Programmatic Advertising for Pharma Success

In the fast-paced and highly competitive pharmaceutical industry, leveraging programmatic advertising can be a game-changer for success. Programmatic advertising offers precision targeting, audience segmentation, real-time optimization, and efficiency. Let’s explore these key benefits in more detail.

Precision Targeting and Audience Segmentation

Programmatic advertising allows pharmaceutical brands to reach their target audience with unparalleled precision. By leveraging advanced data analytics and machine learning algorithms, programmatic advertising enables brands to identify and target specific demographics, behaviors, and interests.

With precision targeting, pharmaceutical marketers can focus their advertising efforts on the individuals who are most likely to be interested in their products or services. This not only increases the effectiveness of the campaigns but also optimizes the marketing budget by minimizing wasteful spending.

Moreover, programmatic advertising supports audience segmentation, enabling marketers to create personalized and tailored messages for different segments of their target audience. By understanding the unique needs and preferences of each segment, pharmaceutical brands can deliver highly relevant and engaging advertisements, fostering a stronger connection and increasing the likelihood of conversion.

Real-time Optimization and Efficiency

One of the key advantages of programmatic advertising in the pharmaceutical industry is the ability to optimize campaigns in real-time. Through continuous monitoring and analysis of campaign performance, marketers can make data-driven decisions and make adjustments on the fly.

Real-time optimization allows pharmaceutical brands to identify underperforming ad placements, adjust bidding strategies, and refine targeting parameters to maximize the impact of their advertising efforts. This agility ensures that marketing budgets are allocated effectively and that campaigns are continuously optimized for the best possible results.

Furthermore, programmatic advertising streamlines the advertising process, resulting in increased efficiency. By automating tasks such as ad buying, targeting, and optimization, pharmaceutical marketers can focus their efforts on strategy and creative development. This automation not only saves time and resources but also improves overall campaign performance.

In summary, leveraging programmatic advertising in the pharmaceutical industry provides precision targeting and audience segmentation, as well as real-time optimization and efficiency. By harnessing the power of data and automation, pharmaceutical brands can enhance the effectiveness of their marketing campaigns, connect with their target audience on a deeper level, and drive better results. To learn more about pharma marketing trends, visit our article on pharmaceutical industry marketing trends .

Embracing the Future of Pharma Marketing

To stay competitive in the ever-evolving pharmaceutical industry, embracing the integration of omnichannel marketing and programmatic strategies is crucial. This combination allows pharmaceutical companies to effectively reach their target audience, deliver personalized experiences, and optimize their marketing efforts. Let’s explore how the integration of these two strategies can help pharmaceutical brands stay ahead of the curve.

Integration of Omnichannel and Programmatic Strategies

The integration of omnichannel marketing and programmatic advertising opens up new doors for pharmaceutical companies to engage with their customers in a more meaningful and targeted manner. By combining these strategies, brands can create seamless and synchronized experiences across multiple channels, both online and offline.

Omnichannel marketing ensures that customers receive consistent messaging and experiences across various touchpoints, such as websites, social media platforms, mobile apps, and physical stores. Programmatic advertising, on the other hand, leverages data and automation to deliver targeted ads to the right audience, at the right time, and on the right platforms.

By integrating these two strategies, pharmaceutical companies can create highly personalized and relevant marketing campaigns. For example, using programmatic advertising, brands can identify specific target audiences and serve them personalized ads based on their demographics, interests, and online behavior. These ads can then direct customers to an omnichannel experience, where they can seamlessly navigate through different channels and engage with the brand in a consistent manner.

Staying Ahead of the Curve

In the rapidly changing pharmaceutical industry, staying ahead of the curve is essential for success. By embracing the integration of omnichannel marketing and programmatic strategies, brands can gain a competitive edge and adapt to the shifting landscape.

To effectively stay ahead, pharmaceutical companies should constantly monitor and analyze market trends and consumer behavior. This includes keeping a pulse on emerging technologies, tracking digital marketing strategies, and understanding the evolving needs and preferences of their target audience.

Additionally, investing in advanced technologies and tools, such as pharma marketing automation , can streamline processes and enhance the implementation of omnichannel and programmatic strategies. These tools enable data-driven decision-making, real-time optimization, and efficient campaign management.

By embracing the integration of omnichannel marketing and programmatic strategies, pharmaceutical brands can position themselves at the forefront of the industry. This integration allows for personalized and targeted marketing, improved customer experiences, and optimized campaign performance. As the future of pharma marketing continues to evolve, companies that adapt and harness the power of these strategies will be better equipped to thrive in the dynamic pharmaceutical landscape.

Related Articles

Maximizing HCP Engagement: Leveraging Data and Analytics for Effective Omnichannel Strategies

Accelerating Patient and HCP Activation Through Omnichannel Orchestration

Transforming Pharma Engagement: In-Depth Case Studies on Successful Omnichannel Strategies

Unleashing Pharma Marketing Potential: Embracing Automation

Ashfield Excellence Academy has relaunched as Nazaré. Visit nazarelearning.com to start reimagining learning with us.

Case studies .

By developing meaningful, tailored learning solutions, PMA can upskill pharma marketing teams to apply marketing excellence thinking in their role. Take a look at how we have done this in the real-life examples below.

DEVELOPING A MARKETING ONBOARDING CURRICULUM

DELIVERING A BLENDED-LEARNING MARKETING CURRICULUM AND COMMUNICATIONS PLAN

APPLYING MARKETING EXCELLENCE TO LAUNCH STRATEGY DEVELOPMENT

DEVELOPING A CUSTOMER-CENTRIC MARKETING MINDSET

• Quality Assurance
• Quality Control
• Manufacturing
• Marketing Case Study
• Sales Case Study
• QA Job Starter
• QC Job Starter
• GPAT Preparation
• LEARNING POINTS
• Program Calendar
• Corporate Trainings

Get access to all Pharma Marketing Case Studies with a subscription. More Skills & Case Studies will be added in due course.

Pharma Marketing Case Studies

Enhance your pharma marketing skills through practical case studies. Explore real-world examples to simplify learning and apply new skills directly to your profession.

• The pharma marketing case studies are prepared using AI + Human intelligence.
• All names and scenarios in our case studies are fictional. Any resemblance is to be considered purely coincidental.
• If more case studies & skills are added in due course, you will also get access to those case studies.

Explore this 'Free Case Study' before purchasing the package!

Effective Customer Communication | Case Study

Communication.

Implementing a Communication Protocol | Case Study

Improving Sales Communication | Case Study

Effective Communication Strategies | Case Study

Crisis Communication Management | Case Study

Effective Cross-Functional Collaboration | Case Study

Territory Management Collaboration | Case Study

Medical Affairs Collaboration | Case Study

Thought Leadership Educational Symposia | Case Study

Exploring External Partnerships | Case Study

Project management.

Product Launch Campaigns | Case Study

Driving Engagement and Profitability | Case Study

KOL Engagement Programs | Case Study

Digital Marketing Campaign | Case Study

Product Lifecycle | Case Study

Business analysis.

Market Entry Strategy for a New Drug | Case Study

Maximizing Pharma Product Lifecycle | Case Study

Pricing Strategy for Specialty Drugs | Case Study

Market Expansion into Emerging Markets | Case Study

Competitor Analysis and Brand Positioning | Case Study

Problem solving.

Overcoming Market Saturation | Case Study

Competitive Threats | Case Study

Integrating Patient-Centricity | Case Study

Harnessing Real-World Evidence | Case Study

Strategic Market Expansion | Case Study

• Marketing Case Study Package
• Sales Case Study Package
• My First Job Module
• Hall Of Fame – Quizzes
• CPhE Learning Points
• Learners Leaderboard
• Join as Student
• Get Your Own LMS
• Install App
• Humans of PHARMA
• Course Category
• Download Certificate
• Terms & Conditions
• Privacy Policy
• Refund & Cancellation

If you don’t already have an account click the button below to create your account.

Registration Already have an account? Sign In

• SUGGESTED TOPICS
• The Magazine
• Newsletters
• Managing Yourself
• Managing Teams
• Work-life Balance
• The Big Idea
• Data & Visuals
• Reading Lists
• Case Selections
• HBR Learning
• Topic Feeds
• Account Settings
• Email Preferences

Pharmaceutical industry

What does it take to redesign an industry.

• Christopher Meyer
• From the March 2013 Issue

Managing Authenticity: The Paradox of Great Leadership

• Gareth Jones
• From the December 2005 Issue

Who Goes, Who Stays? (HBR Case Study)

• David A. Light
• January 01, 2001

Finding the Perfect Pace for Product Launches

• Harvard Business Review
• From the July–August 2018 Issue

Turning Great Strategy into Great Performance

• Michael C. Mankins
• Richard Steele
• July 01, 2005

What It Takes to Lead a Disease Research Foundation

• Kathy Giusti
• Richard G. Hamermesh
• August 18, 2020

Focus on Pharmaceuticals: Industry Structure and Competitive Advantage

• Anita M. McGahan
• From the November–December 1994 Issue

The CEO of Pfizer on Developing a Vaccine in Record Time

• Albert Bourla
• From the May–June 2021 Issue

How Merck Is Trying to Keep Disrupters at Bay

• Frank V. Cespedes
• Jay Galeota
• Michael Wong
• June 08, 2015

Putting Customers in the “Wish Mode”

• Jason Magidson
• Gregg Brandyberry
• From the September 2001 Issue

Scientific Management at Merck: An Interview with CFO Judy Lewent

• Nancy A. Nichols
• From the January–February 1994 Issue

Will Disruptive Innovations Cure Health Care?

• Clayton M. Christensen
• Richard M.J. Bohmer
• John Kenagy
• From the September–October 2000 Issue

Adopting AI in Health Care Will Be Slow and Difficult

• October 18, 2019

Scanning the Periphery

• George S. Day
• Paul J.H. Schoemaker
• From the November 2005 Issue

What B2B Customers Really Expect

• Philip Kreindler
• Gopal Rajguru
• From the April 2006 Issue

"A Players" or "A Positions"? The Strategic Logic of Workforce Management

• Mark A. Huselid
• Richard W. Beatty
• Brian E. Becker

All Strategy Is Local

• Bruce C. Greenwald
• September 01, 2005

How Pharma Companies Game the System to Keep Drugs Expensive

• April 06, 2017

Conquering a Culture of Indecision (HBR Classic)

• January 01, 2006

How Pharma Can Fix Its Reputation and Its Business at the Same Time

• Damiano de Felice
• February 03, 2017

Puritan Drug Co.

• Rowland T. Moriarty Jr.
• February 11, 1985

Merck Latin America (D): Mexico

• Michael Beer
• James Weber
• March 12, 2001

23andMe: A Virtuous Loop

• Jeffrey M. Conn
• Robert E. Siegel
• February 06, 2020

Managing Drugs on the Forefront of Personalized Medicine: The Erbitux and Vectibix Story

• Raju Kucherlapati
• Rachel Gordon
• November 06, 2009

CIBA-GEIGY Pharmaceuticals: Pharma International

• N. Craig Smith
• John A. Quelch
• July 28, 1989

Glenmark Generics Inc.: Launch @ Risk

• Peter C Bell
• Ramasastry Chandrasekhar
• June 15, 2015

Zandu Pharmaceutical Works: The Takeover Bid (B)

• Kavil Ramachandran
• Jayshree Suresh
• Navneet Bhatnagar
• November 01, 2014

OrganiGram: Navigating the Cannabis Industry with "Grey Knowledge"

• August 09, 2017

Gilead: Hepatitis-C Access Strategy (A)

• V. Kasturi Rangan
• Vikram Rangan
• David E. Bloom
• October 28, 2014

Novartis Pharma: The Business Unit Model

• Srikant M. Datar
• Carin-Isabel Knoop
• Cate Reavis
• January 22, 2001

Biovail Corporation: Revenue Recognition and FOB Sales Accounting

• Craig J Chapman
• April 07, 2009

Genetic Testing and the Puzzles We Are Left To Solve (D): Discovery of "Nonpaternity"

• R. Edward Freeman
• Stacy Pierce
• March 30, 2000

Negotiating Strategic Alliances

• Michael D. Watkins
• June 20, 2002

Novartis: Leading a Global Enterprise

• William W. George
• Krishna G. Palepu
• May 27, 2013

Actigall: Managing the Divestment of Mature Drugs

• Stuart C. Gilson
• David Kiron
• May 02, 2007

Pharmaceutical Industry: Challenges in the New Century

• Stephen P. Bradley
• February 12, 2003

Merck: Managing Vioxx (A)

• Robert Simons
• Kathryn Rosenberg
• Natalie Kindred
• April 20, 2009

The Business of Pain: Johnson & Johnson and the Promise of Opioids

• Erik Snowberg
• Trevor Fetter
• Amy W. Schulman
• December 16, 2019

David Hysong and SHEPHERD Therapeutics

• Ananth Raman
• November 05, 2018

Lundbeck A/S

• Lee Remmers
• December 01, 2000

Zandu Pharmaceutical Works: The Takeover Bid (A), Teaching Note

Cesim Firm: General Business Management Simulation

• October 12, 2018

Popular Topics

Partner center.

Academia.edu no longer supports Internet Explorer.

To browse Academia.edu and the wider internet faster and more securely, please take a few seconds to  upgrade your browser .

Enter the email address you signed up with and we'll email you a reset link.

• We're Hiring!
• Help Center

ESSAYS ON PHARMACEUTICAL MARKETING WITH A CASE STUDY COMPANY

2018, ABC Research Alert

The objective of this thesis was to design a marketing strategy plan for a case company in Thailand. Due to confidentiality, the case company is blinded as Company X, who has also sponsored primary research surveys included in the study. The ideal outcome of this thesis was to design a marketing strategy plan to help the case company become a successful pharmaceutical company and strengthen topline business performance over the near future period in 2019-2021. Quantitative research methods were mainly used in this dissertation research. A single case study with two marketing hypotheses were utilized as research techniques. Primary survey pen-and paper based questionnaires and the interviews were the major information sources of the empirical data for the research, complemented with secondary data sources. The theoretical framework aims to find knowledge for compiling the main elements of the marketing strategy plan in this thesis. A situation analysis and SWOT analysis of the case company were also presented in this thesis. The results of the thesis were tactical marketing plans and marketing strategies for Company X Thailand. Proposed marketing strategy plans were based on the internal and external analyses of the case company.

RELATED TOPICS

•   We're Hiring!
•   Help Center
• Find new research papers in:
• Health Sciences
• Earth Sciences
• Cognitive Science
• Mathematics
• Computer Science
• Academia ©2024